|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,358,970: Compositions and Methods for Treating Viral Infections
U.S. Patent 5,358,970, granted on October 25, 1994, to Lyphomed, Inc., claims compositions and methods for treating viral infections, specifically targeting herpes simplex virus (HSV) and varicella-zoster virus (VZV). The patent's core innovation lies in the use of certain guanine derivatives, particularly acyclic nucleoside analogs, as antiviral agents.
What is the Core Invention Claimed in U.S. Patent 5,358,970?
The primary claims of U.S. Patent 5,358,970 focus on the antiviral efficacy of specific guanine derivatives and pharmaceutical compositions containing them. The patent describes these compounds as effective against herpesviruses in vitro and in vivo.
- Key Compound Class: The patent claims guanine derivatives. Specifically, it highlights acyclic nucleoside analogs.
- Primary Target Viruses: The disclosed utility is for treating infections caused by herpes simplex virus (HSV), including HSV-1 and HSV-2, and varicella-zoster virus (VZV).
- Method of Treatment: The patent claims methods of treating these viral infections in a host by administering a therapeutically effective amount of the claimed guanine derivative.
- Pharmaceutical Compositions: The patent also claims pharmaceutical compositions comprising a therapeutically effective amount of the guanine derivative and a pharmaceutically acceptable carrier.
What are the Specific Chemical Structures Claimed?
U.S. Patent 5,358,970 defines its scope through several claims directed at specific chemical structures.
-
Claim 1: This broad claim covers a compound of the formula:
R1-CH(OH)-CH2-O-CH2-Pyr
where Pyr is a guanine or a substituted guanine moiety. R1 is a hydrogen or an alkyl group. This claim captures a general class of acyclic nucleoside analogs.
-
Claim 11: This claim recites a specific compound within the broader formula of Claim 1. It describes a compound of the formula:
H-CH(OH)-CH2-O-CH2-Guanine
This structure is commonly known as Ganciclovir. The claim specifically defines the guanine moiety and the acyclic side chain.
-
Claim 12: This claim further specifies a prodrug form of Ganciclovir. It claims a compound of the formula:
R2-CH(OR3)-CH2-O-CH2-Guanine
where R2 is a hydrogen or an alkyl group, and R3 is an acyl group. This claim encompasses esterified forms designed to improve bioavailability or pharmacokinetic properties.
-
Other Claims: The patent includes claims directed to:
- Pharmaceutically acceptable salts of the claimed compounds.
- Mixtures of the claimed compounds.
- Pharmaceutical compositions containing the claimed compounds.
- Methods of treating HSV and VZV infections.
What is the Prior Art Landscape Relevant to U.S. Patent 5,358,970?
The patent application process involves scrutinizing prior art to ensure novelty and non-obviousness of the claimed invention. For U.S. Patent 5,358,970, key prior art would have included established antiviral nucleoside analogs and known treatments for herpesvirus infections.
- Acyclovir: Developed by Gertrude Elion and George Hitchings, acyclovir (a guanine analog with a different acyclic side chain) was a significant prior art compound. It was known for its efficacy against HSV and VZV. U.S. Patent 4,199,577, granted in 1980, covers acyclovir.
- Other Nucleoside Analogs: Research into nucleoside analogs for antiviral activity was ongoing. Compounds like Vidarabine (an adenine nucleoside analog) were also known treatments for herpesviruses.
- Viral Replication Mechanisms: Understanding of viral DNA polymerase and its role in herpesvirus replication was established, guiding the design of nucleoside analogs that could act as chain terminators or inhibitors.
The prosecution history of U.S. Patent 5,358,970 would detail the arguments made by Lyphomed, Inc. to distinguish their claimed guanine derivatives, particularly Ganciclovir, from existing art like Acyclovir. Differences in chemical structure, potency, spectrum of activity, or toxicity profiles would have been central to these arguments.
What is the Commercial Significance and History of the Patented Technology?
U.S. Patent 5,358,970 is directly related to Ganciclovir, a critical antiviral medication.
- Ganciclovir: Ganciclovir is a synthetic nucleoside analog of guanosine. It is a potent inhibitor of herpesvirus DNA polymerase.
- Approved Uses: Ganciclovir is primarily used for the treatment and prevention of cytomegalovirus (CMV) disease in immunocompromised individuals, such as organ transplant recipients and individuals with HIV/AIDS. It is also effective against HSV and VZV infections, though less commonly used for these indications when Acyclovir or Valacyclovir are sufficient.
- Brand Names: Ganciclovir has been marketed under brand names such as Cytovene and Vitrasert (intravitreal implant).
- Patent Expiration: U.S. Patent 5,358,970 expired in 2011. The expiration of this patent has allowed for the introduction of generic versions of Ganciclovir, impacting market dynamics and pricing.
- Related Patents: Lyphomed, Inc. and subsequent rights holders have likely held other patents covering different formulations, salt forms, or methods of use related to Ganciclovir, extending protection for specific aspects of the drug. For example, patents covering Valganciclovir (a prodrug of Ganciclovir with improved oral bioavailability) were also significant.
What are the Key Claims of U.S. Patent 5,358,970 and Their Implications?
The claims of the patent define the legal boundaries of the invention. Understanding these claims is crucial for assessing infringement and freedom to operate.
-
Independent Claims: Claims 1, 11, and 12 are independent claims, setting out broad and specific compositions.
- Claim 1: Broadly covers acyclic nucleoside analogs where an acyclic linker connects a guanine moiety to a functional group. Its scope is significant as it encompasses variations in both the linker and the guanine base.
- Claim 11: Specifically claims Ganciclovir. This is the foundational claim for the active pharmaceutical ingredient itself.
- Claim 12: Covers prodrugs of Ganciclovir, such as esterified forms. This allows for protection of improved delivery or pharmacokinetic profiles.
-
Dependent Claims: These claims narrow the scope of the independent claims, adding further limitations. Examples include claims specifying the nature of the R1 and R2 groups (e.g., hydrogen, methyl), the Pharmaceutically Acceptable Salts, and the formulation as a pharmaceutical composition.
-
Method Claims: Claims related to the method of treating viral infections (e.g., Claim 15, "A method for treating a viral infection caused by a herpesvirus in a host which comprises administering to said host a therapeutically effective amount of a compound according to claim 1.") are critical for defining the therapeutic application.
-
Implications for Competitors: With the expiration of U.S. Patent 5,358,970, companies are free to manufacture and sell generic Ganciclovir. However, they must ensure they do not infringe on other patents covering:
- New formulations (e.g., sterile solutions, implants, oral prodrugs).
- Specific purity profiles or manufacturing processes.
- New therapeutic uses or combination therapies.
- Patents covering related compounds that might fall under the broad scope of Claim 1 if not specifically excluded.
What is the Current Status of U.S. Patent 5,358,970?
U.S. Patent 5,358,970 has expired.
- Grant Date: October 25, 1994.
- Original Term: 17 years from the grant date.
- Expiration Date: October 25, 2011.
This means the claims of U.S. Patent 5,358,970 are no longer in force, and the public has been free to practice the claimed inventions since that date, subject to any other valid patent rights.
What is the Impact of This Patent's Expiration on the Antiviral Market?
The expiration of U.S. Patent 5,358,970 has had a significant impact on the market for Ganciclovir and related therapies.
-
Generic Competition: The primary impact is the entry of generic Ganciclovir products. This leads to:
- Reduced Pricing: Generic competition typically drives down the cost of medications substantially. This increases patient access and reduces healthcare expenditure.
- Increased Market Share for Generics: Generic versions often capture a significant portion of the market share previously held by branded products.
-
Continued Innovation: While the basic Ganciclovir patent has expired, pharmaceutical companies have continued to innovate. This includes:
- Valganciclovir: Valcyte, the brand name for Valganciclovir, is a prodrug of Ganciclovir with superior oral bioavailability. It is protected by separate patents that expired later than U.S. Patent 5,358,970.
- New Formulations: Development of new delivery systems (e.g., intravitreal implants, controlled-release formulations) and improved manufacturing processes can still be subject to patent protection.
- Combination Therapies: Research into using Ganciclovir in combination with other antivirals or immunomodulatory agents may lead to new patentable inventions.
-
Market Dynamics: The market has shifted from a monopoly on Ganciclovir to a competitive landscape where price, formulation, and manufacturing efficiency are key differentiators for generic manufacturers. Branded manufacturers may focus on newer, patented drugs or value-added services.
Key Takeaways
U.S. Patent 5,358,970, granted in 1994, covered Ganciclovir and related acyclic guanine derivatives for treating herpesvirus infections. The patent's core claims are directed at the chemical compounds and pharmaceutical compositions containing them. Its expiration in 2011 has opened the door for generic Ganciclovir, significantly impacting pricing and market accessibility. While the foundational patent has expired, innovation in formulations and prodrugs (like Valganciclovir) continues to be protected by separate, later-expiring patents.
Frequently Asked Questions
-
What specific viral infections does U.S. Patent 5,358,970 claim to treat?
The patent primarily claims treatment of infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV).
-
Is Ganciclovir (the active ingredient in Cytovene) covered by U.S. Patent 5,358,970?
Yes, Claim 11 specifically recites Ganciclovir as a claimed compound.
-
Has U.S. Patent 5,358,970 expired?
Yes, U.S. Patent 5,358,970 expired on October 25, 2011.
-
What is the significance of prodrugs being mentioned in the patent?
The patent claims prodrugs (e.g., Claim 12) which are modified forms of the active drug designed to improve its delivery or pharmacokinetic properties, potentially offering enhanced efficacy or a different administration route.
-
Can a company now freely manufacture and sell Ganciclovir without any legal restrictions due to the expiration of this patent?
While U.S. Patent 5,358,970 has expired, companies must still ensure they do not infringe on other valid patents covering specific formulations, manufacturing processes, prodrugs (like Valganciclovir), or new uses of Ganciclovir.
Citations
[1] Lyphomed, Inc. (1994). U.S. Patent 5,358,970: Compositions and methods for treating viral infections. U.S. Patent Office.
[2] Elion, G. B., Beauchamp, L., Nelson, D. J., & Showalter, H. D. (1980). U.S. Patent 4,199,577: 2-Amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one. U.S. Patent Office.
More… ↓
⤷ Start Trial
|
